Document Classification

Section Type: METHODS

Text: In this open-label, multicentre, phase 2, randomised trial, patients with postoperative pathological stage II (ypT3-4N0) or III (ypTanyN1-2) rectal cancer after preoperative fluoropyrimidine-based chemoradiotherapy and total mesorectal excision were recruited and randomly assigned (1:1) via a web-based software platform to receive adjuvant chemotherapy with either four cycles of fluorouracil and leucovorin (fluorouracil 380 mg/m (2) and leucovorin 20 mg/m (2) on days 1-5, every 4 weeks) or eight cycles of FOLFOX (oxaliplatin 85 mg/m (2), leucovorin 200 mg/m (2), and fluorouracil bolus 400 mg/m (2) on day 1, and fluorouracil infusion 2400 mg/m (2) for 46 h, every 2 weeks).